The MarketWatch News Department was not involved in the creation of this content. -- First--in--class DARKFOX--targeting bispecific T cell engager: ENA101 is designed to selectively recognize the ...
The antitumor efficacy of immune cell engagers that bind two targets on the same immune cell is limited by structural constraints, leading to incomplete coengagement and uncoordinated signaling. Here, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results